2024-519460-40-00招募中4 期
Randomized, double-blind, parallel group clinical trial to evaluate the efficacy and safety of PRGF eye drops as a treatment for dry eye disease in patients with glaucoma
Biotechnology Institute I Mas D S.L.1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2024年11月28日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- - Change in the degree of ocular staining at 6 months using the Oxford scale. - Evolution of symptomatology at 6 months according to the Ocular Surface Disease Index (OSDI).
研究概览
简要总结
To evaluate the efficacy of PRGF eye drops in relieving dry eye symptomatology in glaucoma patients.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent.
- •Man or woman over 50 years of age.
- •Controlled glaucoma or ocular hypertension (OHT) requiring pharmacological treatment with at least one active ingredient with preservatives and presenting ocular dryness.
- •The patient must have discontinued treatment with artificial tears at least one week prior to this visit.
- •Diagnosis of moderate to severe dry eye syndrome defined by OSDI score ≥
- •Patient who has at least one eye that meets the following requirements: - Total ocular staining (cornea and conjunctiva) with Oxford scale grade between grade 2 to
- •At least one of the following objective signs: o Schirmer's test ≥ 3 mm/5 min and ≤ 9 mm/5 min, o TBUT: <10 seconds.
- •Patients with glaucoma: optic nerve involvement compatible with this disease (focal or diffuse thinning of the neuroretinal ring), objectified by previous optical coherence tomography (OCT), independent of whether they have campimetric defect and IOP figure.
- •Patients with OHT: IOP > 21 mmHg in at least two measurements, without optic nerve involvement, requiring ocular hypotensive treatment.
- •Absence of progression of OHT or glaucoma in the year prior to the start of the study, objectifiable by OCT and/or campimetry.
排除标准
- •Exclusion criteria of ophthalmic nature in at least one eye
- •Ocular rosacea
- •History of ocular trauma or ocular infection in the previous 3 months.
- •History of ocular allergy
- •History of uveitis (last episode less than 6 months).
- •History of inflammatory corneal ulcer in the last 12 months.
- •Ocular surgery in the previous 3 months or foreseen indication for ocular surgery during the duration of the study.
- •Systemic/non-ophthalmic exclusion criteria
- •Known or suspected hypersensitivity to one of the components of the investigational product or ancillary products.
- •History of any active systemic condition incompatible with the investigation or which, in the investigator's judgment, may interfere with the results of the investigation or with patient safety
- •Active allergic rhinitis or allergic rhinitis likely to reactivate during the investigation.
- •Any other medical or surgical history, disorder or disease likely to require or modify systemic medication during the investigation (systemic medication must be stable in the three months prior to screening).
- •Exclusion criteria specifically related to women of childbearing potential
- •Pregnancy or breastfeeding
- •Women of childbearing age who are not using reliable contraceptive methods (oral contraceptives, IUD, subdermal contraceptive implants, vaginal ring, patch) and who have not undergone surgical sterilization.
- •Exclusion criteria relating to factors of a general nature
- •Inability of the patient to understand the research procedures or to give informed consent.
- •Non-compliance on the part of the patient (e.g., refusal to attend a visit or to complete a questionnaire or study tests);
- •Participation in this trial at the same time as participation in another trial.
- •Participation in this trial during the opt-out period of another trial;
- •Patients who are institutionalized by court or regulatory order, who are confined in psychiatric facilities, correctional institutions, or state institutions, and employees of the sponsor's research facilities or company.
- •Patient not covered by the public health system.
- •Patient under guardianship or court-ordered guardianship.
- •Patients who have used or use a prohibited treatment (or perform a prohibited modification of the therapeutic regimen).
- •Patients diagnosed with coagulopathies or autoimmune diseases, infection or tumor in the area of application, or retinopathy.
- •Patients with hepatic insufficiency.
研究组 & 干预措施
-
Active Comparator
Participants receiving -
干预措施: - (Drug)
结局指标
主要结局
- Change in the degree of ocular staining at 6 months using the Oxford scale. - Evolution of symptomatology at 6 months according to the Ocular Surface Disease Index (OSDI).
- Change in the degree of ocular staining at 6 months using the Oxford scale. - Evolution of symptomatology at 6 months according to the Ocular Surface Disease Index (OSDI).
次要结局
- - Change in the degree of ocular staining at 3 months using the Oxford scale.
- Change in symptomatology at 3 months according to the Ocular Surface Disease Index (OSDI).
- Change in the amount of tears produced at 3 and 6 months using the Schirmer test.
- Change in tear breakup time (TBUT) at 3 and 6 months.
- - Evolution of conjunctival hyperemia at 3 and 6 months using the McMonnies photographic scale.
- - Evolution of corrected distance visual acuity in both eyes at 3 and 6 months.
- - Change in the concentration of inflammation biomarkers S100A8 and MMP-9 in tears at 3 and 6 months post-treatment.
- Demographic and identification variables - Patient code - Age - Sex - Toxic habits (alcohol, tobacco)
- Safety variables - Global tolerance assessed by the investigator at 3 and 6 months. - Patient-assessed global tolerance at 3 and 6 months. - Type and frequency of ocular adverse events. - Type and frequency of systemic adverse events.
研究者
Mohammad Alkhraisat Almasoud
Scientific
Biotechnology Institute I Mas D S.L.
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Randomized clinical trial to evaluate the use of PRGF eye drops in patients with dry eye disease2023-507357-15-01Biotechnology Institue I Mas D S.L.54
已完成
不适用
Managing Dry Eye in Patients Using Glaucoma DropsDry EyeNCT06158984He Eye Hospital60
尚未招募
不适用
Evaluate the Efficacy and Safety of Glaucoma Implant in Primary Open Angle GlaucomaGlaucomaNCT05892185Mingche Biotechnology CO., LTD20
已完成
3 期
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.Dry Eye SyndromesNCT02553772Allergan242
已完成
1 期
IVIG-eye Drops Treatment for Dry Eye DiseaseDry EyeNCT03992482Sandeep Jain, MD27